Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.4399 +0.0159 (+3.75%)
Streaming Delayed Price Updated: 3:12 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market' ↗
U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark indices were mixed in premarket. 
Via Benzinga
Topics Stocks
News headline image
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Study is expected to deliver final device data and documentation needed for planned FDA IND submission 
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
Via Investor Brand Network
News headline image
Silo Pharma Announces Closing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
InvestorkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Announces Pricing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment ↗
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial. 
Via Stocktwits
News headline image
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
Via Investor Brand Network
News headline image
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models ↗
Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.